Ceftobiprole
Phase 1Small molecule
Basilea PharmaceuticaCeftobiprole is one of 30 small molecule programs targeting Ventilator-Associated Pneumonia. It is currently in Phase 1.
1
Indications
8
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Ventilator-Associated Pneumonia
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Merrem
BB. Braun Medical Inc.
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Amikin
IInsmed Incorporated
Approved
Primaxin
PfizerPhase 3
Coly-Mycin M
PParkedale
Phase 3
Bactrim
UUniversity of California, San Francisco
Phase 3
Zocor
OOrganon and Co
Phase 3
Avycaz
PPhiladelphia Eye Associates
Phase 3
Betadine
BBecton, Dickinson and Company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Antibiotic Therapy1 trial
End-Stage Renal Disease1 trial
Pediatric Patients1 trial
Ventilator-Associated Pneumonia1 trial
3 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ceftobiprole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company